(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of -3.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.04%.
Mimedx Group's revenue in 2026 is $389,416,000.On average, 7 Wall Street analysts forecast MDXG's revenue for 2026 to be $40,934,755,251, with the lowest MDXG revenue forecast at $37,951,372,259, and the highest MDXG revenue forecast at $43,008,079,826. On average, 7 Wall Street analysts forecast MDXG's revenue for 2027 to be $46,012,315,221, with the lowest MDXG revenue forecast at $42,360,165,896, and the highest MDXG revenue forecast at $49,342,741,766.
In 2028, MDXG is forecast to generate $51,791,409,583 in revenue, with the lowest revenue forecast at $48,869,094,341 and the highest revenue forecast at $54,268,377,090.